Clinical trials: Transverse Myelitis
Neuromyelitis Optica Spectrum Disorders (NMOSD)
BLAZE-Limiting Approach in NMOSD
This is an observational cohort study based on data from the hospital-based NMOSD registry (Chinese Medical Research Registration Number MR-31-22-008563; ChiCTR2000030651).
- Trial name
- NCT06888622
- Testing
- Eculizumab administration
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Huashan Hospital
Neuromyelitis Optica Spectrum Disorders
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.
- Trial name
- NCT06068829
- Testing
- Inebilizumab, Rituximab(RTX)
- Volunteers
- 80 people
- Sponsor
- Feng Jinzhou
Neuromyelitis Optica
Neuromyelitis Optica (NMO) & Cetirizine
Neuromyelitis optica (NMO) is an autoimmune disease that affects the central nervous system. Patients have relapses (also known as attacks) which are often quite severe and leave them with significant disability.
- Trial name
- NCT02865018
- Testing
- cetirizine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and immune molecules attack the nervous system as the main…
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis
- Trial name
- CARTinNS (NCT04561557)
- Testing
- CT103A cells, Cyclophosphamide and fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or…
- Trial name
- NCT05909761
- Testing
- UPLIZNA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Amgen
NMO Spectrum Disorder
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
The primary objective of this registry study is to evaluate the therapeutic efficacy and safety profiles of distinct monoclonal antibody-based therapies for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum…
- Trial name
- NCT06885957
- Testing
- Mab Therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
UTI, Neurogenic Bladder
Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)
Due to the damage caused to the spinal cord, patients with spinal cord injury, cauda equina syndrome, multiple sclerosis and transverse myelitis may encounter loss of bladder function, which in turn can lead to a debilitating and…
- Conditions
- UTI, Neurogenic Bladder, Antibiotic Resistance
- Trial name
- PReSuTINeB (NCT02591901)
- Testing
- Uro vaxom
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Buckinghamshire Healthcare NHS Trust
Neuromyelitis Optica Spectrum Disorder
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.
- Trial name
- NCT05891379
- Testing
- Inebilizumab, oral immunosuppressant
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.
- Trial name
- TERMINATOR (NCT07699770)
- Testing
- Crisugabalin
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disorder
Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)
In this research, a prospective, multicenter(Tangdu Hospital of Fourth Military Medical University, Xi'an Gaoxin Hospital of Xi'an Medical College, Xianyang Central Hospital, Baoji Central Hospital, Xi'an Central Hospital, The…
- Trial name
- NCT04256252
- Testing
- Rituximab
- Volunteers
- 108 people
- Sponsor
- Tang-Du Hospital
Neuromyelitis Optica Spectrum Disorder
A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system. NMOSD is a highly relapsing, severely disabling disease.
- Trial name
- NCT05284175
- Testing
- Orelabrutinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Peking Union Medical College Hospital
Neuromyelitis Optica Spectrum Disorder
Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders
Neuromyelitis optica spectrum disorder (NMOSD) is one common demyelinating disease of the central nervous system in young adults, with high rate of disability and recurrence, and poor natural course, which can cause a serious…
- Trial name
- CAMPUS (NCT04064944)
- Testing
- blood purification equipment
- Volunteers
- 144 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Neuromyelitis Optica
Safety and Tolerability of Rituximab in Neuromyelitis Optica
The goal of this research study is to investigate whether Rituximab is safe to use in patients suffering from NMO, or who are at high risk for developing NMO.
- Trial name
- NCT00501748
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Ublituximab (also known as LFB-R603) is a monoclonal antibody that specifically binds to the trans-membrane antigen CD20. The binding induces immune response that causes lysis of B cells.
- Trial name
- NCT02276963
- Testing
- Ublituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Healthy, Multiple Sclerosis
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
Major brain diseases (including neuroimmune diseases, neurodegenerative diseases, and cerebrovascular diseases) are leading causes of death and disability in humans.
- Conditions
- Healthy, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Neurodegenerative Diseases
- Trial name
- NCT06643858
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Neuromyelitis Optica Spectrum Disorders
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients.
- Trial name
- NCT06697535
- Testing
- JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Multiple Sclerosis, Neuromyelitis Optica
MS and NMOSD in African-Americans
This is a prospective study that aims to collect and review neuromyelitis optica spectrum disorder (NMOSD) data from African American patients with a known diagnosis of multiple sclerosis (MS).
- Trial name
- NCT04131673
- Where
- United States
- Sponsor
- Jagannadha R Avasarala
Demyelinating Diseases of the Central Nervous System (DDC)
Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)
Demyelinating Diseases of the Central Nervous System Registry for Patients with Traditional Chinese Medicine (DATE-TCM) is an observational study aiming to better define the multidimensional (epidemiologic, demographic and…
- Trial name
- NCT05415579
- Testing
- Traditional Chinese medicine (TCM)
- Volunteers
- 2,000 people
- Sponsor
- Dongzhimen Hospital, Beijing